Insulet Q2FY26 Results: Revenue up 23% YoY, adjusted EPS rises 41.5%
- Total revenue reached $802 million, up 23.5% YoY on a reported basis
- Adjusted EPS rose 41.5% to $1.66, outpacing revenue growth
- Adjusted operating margin expanded by 140 bps to 19.3%
- Full-year revenue growth guidance revised to 20-22% due to type 2 retention trends
*this image is generated using AI for illustrative purposes only.
Insulet Corporation reported second-quarter fiscal year 2026 results on Wednesday, posting $802 million in total revenue, an increase of 23.5% year-over-year on a reported basis.
The medical device manufacturer highlighted strong demand for its Omnipod system across both US and international markets. Adjusted earnings per share rose 41.5% to $1.66, reflecting significant operating leverage as revenue growth translated into disproportionately stronger profit growth.
Financial Performance Highlights
The company’s profitability expanded alongside top-line growth. Adjusted operating margin increased by 140 basis points to 19.3%, while adjusted gross margin improved by 320 basis points to 72.9%. These gains were attributed to manufacturing productivity improvements at Acton and Malaysia facilities, positive pricing, and volume scale.
| Metric | Q2FY26 | Change (YoY) | Notes |
|---|---|---|---|
| Total Revenue | $802 million | +23.5% | Reported basis |
| Constant Currency Rev Growth | N/A | +22.7% | Excludes FX impact |
| Adjusted EPS | $1.66 | +41.5% | Up from $1.17 |
| Adj. Operating Margin | 19.3% | +140 bps | Expanded profitability |
| Adj. Gross Margin | 72.9% | +320 bps | Driven by productivity |
Regional and Product Dynamics
US Omnipod revenue grew 20% during the quarter, while international Omnipod revenue surged over 35% on a reported basis (33% constant currency). International growth was primarily driven by volume and favorable price mix realization. In the US, more than 85% of new customer starts came from multiple daily injection users, with over 40% of new starts representing patients with type 2 diabetes.
Global new customer starts reached their second-highest level ever, contributing to a 23% growth in the global customer base. The company also noted that Omnipod 5 became the number one insulin pump for new users in Australia and recently launched in Spain.
Guidance Update and Type 2 Challenges
Management revised its full-year 2026 outlook to reflect emerging retention and utilization trends within the type 2 diabetes customer base. The updated guidance now projects total company constant currency revenue growth of 20% to 22%, down from previous expectations. US Omnipod growth is now expected to be 17% to 19%, while international growth was raised to 30% to 32% due to strong first-half performance.
CEO Ashley McEvoy acknowledged that the company underestimated the challenges in retaining type 2 patients during the first 90 days of therapy. To address this, Insulet is expanding its customer care team, adjusting salesforce compensation to reward retention, and refining its sampling program. The company expects these actions to take time to impact results, hence the conservative guidance update.
What the Numbers Show
A key divergence in the data is the relationship between revenue growth and earnings growth. While revenue grew 23.5%, adjusted EPS increased by 41.5%. This indicates substantial operating leverage, where fixed costs are being spread over a larger revenue base, allowing margins to expand even as the company invests in sales force expansion and customer support initiatives. Additionally, the $535 million cash position provides flexibility to fund ongoing innovation, including the upcoming Omnipod 6 launch and the fully closed-loop system for type 2 diabetes.
How will the delayed impact of Insulet's new retention initiatives for Type 2 diabetes patients influence Q3 and Q4 revenue visibility?
What specific competitive threats might emerge as Insulet shifts focus to Type 2 retention while rivals target the same demographic with alternative CGM or pump solutions?
To what extent can the Acton and Malaysia manufacturing productivity gains sustain margin expansion if international volume growth slows due to macroeconomic headwinds?
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
